Does Anthem Cover Metformin?

How Anthem Formularies Work and Where Metformin Lands

Anthem, which operates Blue Cross Blue Shield plans in 14 states, organizes covered drugs into formulary tiers. Tier 1 holds preferred generics and carries the lowest patient cost-sharing. Tier 2 holds non-preferred generics or lower-cost brand drugs. Tier 3 and above hold brand-name or specialty drugs, where your out-of-pocket cost rises sharply.

Generic metformin hydrochloride immediate-release has been on Tier 1 across essentially every Anthem commercial plan since the drug lost patent protection. That status reflects the drug's extremely low acquisition cost, roughly $0.03 to $0.07 per 500 mg tablet at wholesale, and its standing as a first-line agent in both the 2024 American Diabetes Association Standards of Care and the 2023 Endocrine Society Clinical Practice Guideline on Type 2 Diabetes.

Immediate-Release vs. Extended-Release Coverage

Generic metformin ER is also a preferred generic on most Anthem plans, though a small number of regional Anthem subsidiaries place it on Tier 2. The practical difference is a copay of $0 to $10 (Tier 1) versus $10 to $25 (Tier 2). Brand-name Glucophage XR is a different story. Because a bioequivalent generic exists, Anthem typically excludes brand Glucophage XR from coverage outright or places it on Tier 4 or 5 unless you obtain prior authorization demonstrating a medically necessary reason the generic formulation cannot be used.

How to Confirm Your Specific Plan's Tier Assignment

Anthem operates dozens of distinct plan designs, including employer-sponsored PPOs and HMOs, individual and family marketplace plans (ACA), Medicaid managed care (Anthem HealthKeepers, etc.), and Medicare Advantage with Part D drug benefits. Your formulary document is specific to your plan ID. The fastest way to confirm metformin's tier is:

1. Log in at anthem.com and use the drug cost estimator tool.
2. Call the Member Services number on the back of your Anthem ID card.
3. Ask your pharmacy to run a real-time adjudication before you pay.

Does Anthem Require Prior Authorization for Metformin?

For generic metformin IR used to treat type 2 diabetes, prior authorization (PA) is not required on the overwhelming majority of Anthem commercial plans. The drug is a first-line guideline therapy and has been generic for decades, so PA requirements would be administratively unusual.

When Prior Authorization May Apply

PA becomes relevant in two situations. First, if your prescriber writes for brand-name Glucophage or Glucophage XR, Anthem may require a PA demonstrating that the generic formulation caused intolerable adverse effects (most commonly GI symptoms). Second, some Anthem plans apply step therapy to metformin ER: the plan wants to see a documented trial of metformin IR before covering the ER formulation at the preferred tier. This is not universal, but it does occur on certain employer plan designs.

The HealthRX clinical team developed the following decision framework for patients navigating Anthem metformin PA requests:

Step 1. Confirm whether your plan requires step therapy for metformin ER by calling Member Services or checking the formulary exclusion list online.

Step 2. If PA is required, ask your prescriber to submit clinical notes documenting GI intolerance on metformin IR (nausea, diarrhea, or abdominal cramping occurring at doses of 500 mg twice daily or higher).

Step 3. If the PA is denied, request a peer-to-peer review. An Anthem medical director speaks directly with your prescriber to reconsider. Approval rates after peer-to-peer review are substantially higher than initial denial rates.

Step 4. If the plan still denies coverage, a 90-day supply of generic metformin ER 500 mg (180 tablets) at Mark Cuban's Cost Plus Drugs costs approximately $7.40 as of early 2025, making the insurance battle optional.

Off-Label Longevity Use and PA Requirements

Metformin is being studied as an anti-aging intervention. The TAME (Targeting Aging with Metformin) trial, a 6-year multicenter randomized controlled trial funded by the American Federation for Aging Research, is testing metformin 1,500 mg/day in adults aged 65 to 79 without diabetes, with primary endpoints including a composite of cardiovascular disease, cancer, dementia, and death. Results are expected in the late 2020s. Anthem does not list longevity or healthy aging as a covered indication for metformin. Prescribers seeking coverage for off-label use will almost certainly face a PA denial under most Anthem plan designs. The more practical path for these patients is cash-pay pricing, discussed later in this article.

What Does Metformin Cost With Anthem Insurance?

Cost depends on your specific plan, the pharmacy you use, and whether you have met your deductible for the year. The numbers below are representative ranges for in-network retail pharmacies during the 2025 plan year.

Tier 1 Copay Scenarios (Most Anthem Plans)

| Drug | Quantity | Typical Anthem Copay | |---|---|---| | Metformin HCl IR 500 mg (generic) | 60 tablets (30-day) | $0 to $8 | | Metformin HCl IR 1000 mg (generic) | 60 tablets (30-day) | $0 to $10 | | Metformin HCl ER 500 mg (generic) | 60 tablets (30-day) | $0 to $10 | | Metformin HCl ER 750 mg (generic) | 60 tablets (30-day) | $4 to $20 |

High-Deductible Health Plans (HDHP)

If you are enrolled in an Anthem HDHP and have not yet met your annual deductible, you pay the plan's negotiated rate, not a simple copay. The negotiated rate for generic metformin IR at major retail chains is typically $4 to $25 for a 30- or 90-day supply, depending on dose and quantity. Even at the full deductible-phase price, metformin is one of the least expensive drugs in the pharmacy.

Anthem Medicare Advantage and Part D

Medicare Part D plans that Anthem administers are subject to CMS formulary requirements. Generic metformin is covered on all CMS-compliant Part D formularies. As of 2025, CMS caps out-of-pocket spending for insulin and some other diabetes drugs, but metformin is already so inexpensive that the cap rarely affects patients. Check your specific Anthem Medicare Advantage drug formulary (the "Evidence of Coverage" document) for your plan's exact cost tier. The CMS Medicare Part D formulary requirements mandate that metformin appear on the formulary for plans serving patients with type 2 diabetes.

What If Anthem Denies Coverage or the Cost Is Still Too High?

Coverage denial for metformin is uncommon, but if it occurs, or if your deductible leaves you paying more than expected, several options bring metformin to $4 to $20 per month.

Manufacturer and Pharmacy Discount Programs

Because metformin has no branded equivalent actively promoted to consumers (Glucophage's patent expired in 2002), there is no manufacturer coupon from a pharmaceutical company. The savings come from pharmacy-level programs instead.

GoodRx. A GoodRx coupon at major chains (CVS, Walgreens, Walmart, Kroger) brings metformin IR 500 mg, 60 tablets to $4 to $9 in most U.S. Markets. GoodRx coupons cannot be used alongside insurance at the same transaction, so compare the GoodRx cash price to your insurance copay and use whichever is lower.

Mark Cuban Cost Plus Drugs (costplusdrugs.com). Metformin HCl 500 mg, 90 tablets costs approximately $4 to $7 at Cost Plus as of early 2025. Cost Plus charges a transparent markup of 15% over manufacturing cost plus a $3 dispensing fee and $5 shipping.

$4 Generics Lists. Walmart, Kroger, and Publix pharmacy programs offer 30-day supplies of generic metformin for $4 and 90-day supplies for $10 without any coupon or insurance required. Eligibility does not depend on insurance status.

State Pharmaceutical Assistance Programs

Several states where Anthem operates Medicaid managed care plans have additional pharmaceutical assistance for patients who fall into coverage gaps. Contact your state's Medicaid office or your Anthem case manager to ask about Extra Help (Low Income Subsidy) programs if you are on a Medicare Part D plan.

Metformin's Clinical Evidence: Why Anthem Covers It

Understanding why Anthem places metformin on Tier 1 requires understanding the drug's evidence base. Anthem formulary committees follow clinical practice guidelines and assess cost-effectiveness.

Type 2 Diabetes Evidence

The UK Prospective Diabetes Study (UKPDS), which enrolled 1,704 overweight patients with newly diagnosed type 2 diabetes, showed that metformin reduced all-cause mortality by 36% and diabetes-related endpoints by 32% compared to conventional diet therapy over a median 10.7-year follow-up (P<0.01 for both comparisons). [1] This landmark trial remains a foundational basis for guideline-driven metformin prescribing.

The 2024 ADA Standards of Medical Care in Diabetes state: "Metformin is recommended as a first-line pharmacological agent for the treatment of type 2 diabetes in most patients, given its established efficacy, safety profile, low cost, and weight-neutral to weight-reducing effects." [2] That explicit guideline language gives Anthem strong grounds to cover the drug at the lowest possible tier.

Metformin lowers HbA1c by approximately 1.0% to 1.5% as monotherapy, a magnitude confirmed across meta-analyses including a Cochrane systematic review (94 trials, N=8,gold) covering head-to-head comparisons with sulfonylureas and thiazolidinediones. [3]

Cardiovascular and Weight Considerations

Unlike sulfonylureas, metformin does not cause hypoglycemia when used as monotherapy. Unlike thiazolidinediones such as pioglitazone, it does not cause fluid retention or increase fracture risk. The Endocrine Society's 2023 clinical practice guideline notes that metformin may produce modest weight reduction of 1 to 3 kg over 12 to 24 weeks in patients with type 2 diabetes, which adds to its value compared to weight-neutral or weight-positive alternatives. [4]

The Longevity Angle: TAME and Observational Data

A frequently cited observational analysis published in Aging Cell (2014) examined 78,241 metformin-treated type 2 diabetes patients and 12,222 sulfonylurea-treated patients matched to 78,227 non-diabetic controls. Metformin-treated patients had modestly longer survival than matched non-diabetic controls (hazard ratio 0.85, P<0.001), a finding that sparked intense interest in metformin as a geroprotective drug. [5] The TAME trial is designed to test this hypothesis in a pre-registered, placebo-controlled setting.

Dr. Nir Barzilai, principal investigator of the TAME trial and director of the Institute for Aging Research at Albert Einstein College of Medicine, stated in a 2023 interview with the National Institute on Aging: "Metformin is one of the best candidates we have because it targets multiple aging mechanisms simultaneously, including mTOR, AMPK, and mitochondrial complex I."

Whether that evidence will eventually translate into Anthem coverage for non-diabetic longevity use is an open question. Currently it does not.

Anthem Metformin Coverage for Specific Patient Groups

Patients With Prediabetes

The ADA 2024 Standards of Care state that metformin may be considered for patients with prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7% to 6.4%), particularly those who are obese, aged <60 years, or have a history of gestational diabetes, with a recommendation grade of B. [2] Anthem coverage for prediabetes is plan-dependent. Some Anthem commercial plans cover metformin for prediabetes with an appropriate ICD-10 diagnosis code (R73.09, "other abnormal glucose"), while others require the prescriber to document a type 2 diabetes diagnosis. Confirm with your plan before the prescription is submitted.

Women With Polycystic Ovary Syndrome (PCOS)

Metformin is used off-label in PCOS to improve insulin sensitivity and restore ovulatory cycles. The Endocrine Society PCOS Guideline recommends metformin for menstrual irregularity in PCOS. [6] Anthem coverage for this indication also varies by plan. Some plans cover it under the metabolic syndrome diagnosis; others classify it as off-label and require PA. Ask your prescriber to document insulin resistance with a fasting insulin level or HOMA-IR calculation to strengthen any PA submission.

Patients on GLP-1 Receptor Agonists

Many patients use metformin alongside semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). Anthem covers metformin at its standard tier regardless of whether you are also prescribed a GLP-1 agent, as the two drugs work through complementary mechanisms and are commonly co-prescribed per ADA guidelines. [2]

How to Appeal an Anthem Metformin Coverage Denial

If Anthem denies coverage for metformin under any circumstance, you have legally protected appeal rights under the Affordable Care Act and ERISA.

Internal Appeal

File an internal appeal within 180 days of the denial. Submit your prescriber's clinical notes, the ICD-10 diagnosis code, and a letter of medical necessity. Anthem must respond to urgent appeals within 72 hours and non-urgent appeals within 30 days, per CMS requirements.

External Review

If the internal appeal fails, request external review by an independent review organization (IRO). The ACA mandates that insurers comply with IRO decisions for non-grandfathered plans. External review overturns insurer denials in approximately 39% to 60% of cases across disease categories, according to Kaiser Family Foundation analysis of ACA marketplace plans.

State Insurance Commissioner

Anthem plans are licensed by state insurance departments. Filing a complaint with your state's insurance commissioner creates a formal record and often prompts Anthem to re-examine borderline denials.

Key Questions to Ask Your Anthem Plan Before Filling Metformin

Getting clear answers upfront saves time and prevents surprise bills at the pharmacy counter.

1. Is generic metformin hydrochloride immediate-release on my formulary, and at which tier?
2. Is generic metformin ER on my formulary, and does step therapy apply?
3. What ICD-10 diagnosis codes will trigger coverage without PA?
4. Does my plan cover metformin for prediabetes (R73.09) or PCOS (E28.2)?
5. Have I met my deductible, and will I pay a copay or the negotiated rate?

Your Anthem Member Services team can answer all five questions using your member ID and plan code.